Biopharmaceutical Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Description

The global biopharmaceuticals market is witnessing a significant upswing. Biopharmaceuticals, the forefront of therapeutic innovation, are leading the charge towards a future where treatments are not only more effective but also tailor-made for individual patient needs.

Market Growth Drivers and Trends

The biopharmaceutical industry stands on the brink of exponential growth, with projections indicating a robust increase in market value. Currently valued at an impressive US$ 509 billion, the market is anticipated to surge at a compound annual growth rate (CAGR) of 11.4%. This growth trajectory is fueled by a growing inclination towards targeted therapy, which promises higher efficacy and reduced side effects, and an impressive influx of investments in research and development.

The emergence of biosimilars represents a particularly lucrative avenue for manufacturers, promising to introduce competition and reduce costs in a market traditionally dominated by high-priced biologics. Similarly, protein therapeutics are gaining traction, heralded for their precision in targeting and treating various diseases.

Impact of COVID-19 on the Biopharmaceutical Market

The ongoing COVID-19 pandemic has underscored the indispensable role of biopharmaceuticals in addressing global health crises. With healthcare spending on the rise, the industry is poised to experience further growth, driven by the urgent need for effective treatments and vaccines. This surge in demand highlights the critical importance of biopharmaceuticals in combating current and future pandemics.

Geographical Insights

North America remains at the forefront of the global biopharmaceuticals market, reflecting its advanced healthcare infrastructure and technological advancements. The region holds a substantial market share, expected to witness significant growth over the forecast period. However, the Asia Pacific region is also poised for rapid expansion, driven by its burgeoning healthcare sector and untapped potential.

Competitive Landscape and Innovations

The biopharmaceuticals market is characterized by intense competition and continuous innovation. Industry giants such as Pfizer, Inc., F. Hoffmann-La Roche AG, Johnson & Johnson Services, Inc., and others are at the forefront, deploying cutting-edge technologies and launching novel products to secure their market dominance. These companies, along with other key players like Sanofi, Amgen Inc., and Merck & Co., Inc., are leveraging their R&D capabilities to introduce cost-effective and highly efficient biopharmaceuticals to the market.

Challenges and Market Dynamics

Despite its promising growth, the biopharmaceuticals market faces several challenges. The high cost of biopharmaceutical drugs, coupled with the advent of low-cost biosimilars, presents a significant hurdle. Moreover, concerns over potential side effects continue to be a major restraint. However, the benefits of biopharmaceuticals, especially in treating chronic and previously untreatable conditions, far outweigh these challenges.

Biopharmaceuticals are proving indispensable in the fight against a range of diseases, from cancer and cardiovascular disorders to rare and neurological conditions. Their ability to improve patient outcomes and quality of life underscores their pivotal role in modern healthcare.

Outsourcing and Strategic Partnerships

A notable trend in the biopharmaceuticals industry is the growing reliance on outsourcing and strategic partnerships, especially with Contract Manufacturing Organizations (CMOs). This approach not only reduces the cost and risk associated with bringing new therapies to market but also facilitates quicker market entry, ensuring that life-saving treatments reach patients in need without undue delay.

Looking Ahead

As we move forward, the global biopharmaceuticals market stands at the cusp of a new era of medical treatment. With ongoing innovations, strategic industry collaborations, and a steadfast commitment to research and development, the future of healthcare looks brighter than ever. The biopharmaceutical industry, with its potential to revolutionize patient care, is poised for unprecedented growth and success.

For more information and to explore the opportunities within the biopharmaceuticals market, connect with our experts and let us guide you through the possibilities tailored to your business objectives.

Market Segmentation

By Type

Monoclonal Antibodies
Recombinant Proteins
Granulocyte-Colony Stimulating Factor (G-CSF)
Interferons
Recombinant Human Insulin
Erythropoietin
Vaccines
Growth Hormones
Purified Proteins
Others

Market Application

Metabolic Disorders
Oncology
Neurological Disorders
Cardiovascular Diseases
Inflammatory and Infectious Diseases
Others

Market by Geography

North America
Europe
Asia
Rest of the World

1. Executive Summary

1.1. Global Biopharmaceutical Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Biopharmaceutical Market Outlook, 2018 - 2031

3.1. Global Biopharmaceutical Market Outlook, by Type, Value (US$ Bn), 2018 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Monoclonal Antibodies
  - 3.1.1.2. Recombinant Proteins
  - 3.1.1.3. Granulocyte-Colony Stimulating Factor (G-CSF)
  - 3.1.1.4. Interferons
  - 3.1.1.5. Recombinant Human Insulin
  - 3.1.1.6. Erythropoietin
  - 3.1.1.7. Vaccines
  - 3.1.1.8. Growth Hormones
  - 3.1.1.9. Purified Proteins
  - 3.1.1.10. Others
3.2. Global Biopharmaceutical Market Outlook, by Therapeutic Application, Value (US$Bn), 2018 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Metabolic Disorders
  - 3.2.1.2. Oncology
  - 3.2.1.3. Neurological Disorders
  - 3.2.1.4. Cardiovascular Diseases
  - 3.2.1.5. Inflammatory and Infectious Diseases
  - 3.2.1.6. Others
3.3. Global Biopharmaceutical Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
- 3.3.1. Key Highlights
  - 3.3.1.1. North America
  - 3.3.1.2. Europe
  - 3.3.1.3. Asia Pacific
  - 3.3.1.4. Latin America
  - 3.3.1.5. Middle East & Africa

4. North America Biopharmaceutical Market Outlook, 2018 - 2031

4.1. North America Biopharmaceutical Market Outlook, by Type, Value (US$ Bn), 2018 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Monoclonal Antibodies
  - 4.1.1.2. Recombinant Proteins
  - 4.1.1.3. Granulocyte-Colony Stimulating Factor (G-CSF)
  - 4.1.1.4. Interferons
  - 4.1.1.5. Recombinant Human Insulin
  - 4.1.1.6. Erythropoietin
  - 4.1.1.7. Vaccines
  - 4.1.1.8. Growth Hormones
  - 4.1.1.9. Purified Proteins
  - 4.1.1.10. Others
4.2. North America Biopharmaceutical Market Outlook, by Therapeutic Application, Value (US$ Bn), 2018 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Metabolic Disorders
  - 4.2.1.2. Oncology
  - 4.2.1.3. Neurological Disorders
  - 4.2.1.4. Cardiovascular Diseases
  - 4.2.1.5. Inflammatory and Infectious Diseases
  - 4.2.1.6. Others
- 4.2.2. BPS Analysis/Market Attractiveness Analysis
4.3. North America Biopharmaceutical Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. U.S. Biopharmaceutical Market by Type, Value (US$ Bn), 2018 - 2031
  - 4.3.1.2. U.S. Biopharmaceutical Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
  - 4.3.1.3. Canada Biopharmaceutical Market by Type, Value (US$ Bn), 2018 - 2031
  - 4.3.1.4. Canada Biopharmaceutical Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
- 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Biopharmaceutical Market Outlook, 2018 - 2031

5.1. Europe Biopharmaceutical Market Outlook, by Type, Value (US$ Bn), 2018 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Monoclonal Antibodies
  - 5.1.1.2. Recombinant Proteins
  - 5.1.1.3. Granulocyte-Colony Stimulating Factor (G-CSF)
  - 5.1.1.4. Interferons
  - 5.1.1.5. Recombinant Human Insulin
  - 5.1.1.6. Erythropoietin
  - 5.1.1.7. Vaccines
  - 5.1.1.8. Growth Hormones
  - 5.1.1.9. Purified Proteins
  - 5.1.1.10. Others
5.2. Europe Biopharmaceutical Market Outlook, by Therapeutic Application, Value (US$ Bn), 2018 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Metabolic Disorders
  - 5.2.1.2. Oncology
  - 5.2.1.3. Neurological Disorders
  - 5.2.1.4. Cardiovascular Diseases
  - 5.2.1.5. Inflammatory and Infectious Diseases
  - 5.2.1.6. Others
- 5.2.2. BPS Analysis/Market Attractiveness Analysis
5.3. Europe Biopharmaceutical Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Germany Biopharmaceutical Market by Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.2. Germany Biopharmaceutical Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
  - 5.3.1.3. U.K. Biopharmaceutical Market by Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.4. U.K. Biopharmaceutical Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
  - 5.3.1.5. France Biopharmaceutical Market by Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.6. France Biopharmaceutical Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
  - 5.3.1.7. Italy Biopharmaceutical Market by Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.8. Italy Biopharmaceutical Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
  - 5.3.1.9. Turkey Biopharmaceutical Market by Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.10. Turkey Biopharmaceutical Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
  - 5.3.1.11. Russia Biopharmaceutical Market by Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.12. Russia Biopharmaceutical Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
  - 5.3.1.13. Rest of Europe Biopharmaceutical Market by Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.14. Rest of Europe Biopharmaceutical Market by Therapeutic Application,Value (US$Bn), 2018 - 2031
- 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Biopharmaceutical Market Outlook, 2018 - 2031

6.1. Asia Pacific Biopharmaceutical Market Outlook, by Type, Value (US$ Bn), 2018 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Monoclonal Antibodies
  - 6.1.1.2. Recombinant Proteins
  - 6.1.1.3. Granulocyte-Colony Stimulating Factor (G-CSF)
  - 6.1.1.4. Interferons
  - 6.1.1.5. Recombinant Human Insulin
  - 6.1.1.6. Erythropoietin
  - 6.1.1.7. Vaccines
  - 6.1.1.8. Growth Hormones
  - 6.1.1.9. Purified Proteins
  - 6.1.1.10. Others
6.2. Asia Pacific Biopharmaceutical Market Outlook, by Therapeutic Application, Value (US$ Bn), 2018 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Metabolic Disorders
  - 6.2.1.2. Oncology
  - 6.2.1.3. Neurological Disorders
  - 6.2.1.4. Cardiovascular Diseases
  - 6.2.1.5. Inflammatory and Infectious Diseases
  - 6.2.1.6. Others
- 6.2.2. Others BPS Analysis/Market Attractiveness Analysis
6.3. Asia Pacific Biopharmaceutical Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. China Biopharmaceutical Market by Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.2. China Biopharmaceutical Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
  - 6.3.1.3. Japan Biopharmaceutical Market by Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.4. Japan Biopharmaceutical Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
  - 6.3.1.5. South Korea Biopharmaceutical Market by Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.6. South Korea Biopharmaceutical Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
  - 6.3.1.7. India Biopharmaceutical Market by Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.8. India Biopharmaceutical Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
  - 6.3.1.9. Southeast Asia Biopharmaceutical Market by Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.10. Southeast Asia Biopharmaceutical Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
  - 6.3.1.11. Rest of Asia Pacific Biopharmaceutical Market by Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.12. Rest of Asia Pacific Biopharmaceutical Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
- 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Biopharmaceutical Market Outlook, 2018 - 2031

7.1. Latin America Biopharmaceutical Market Outlook, by Type, Value (US$ Bn), 2018 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Monoclonal Antibodies
  - 7.1.1.2. Recombinant Proteins
  - 7.1.1.3. Granulocyte-Colony Stimulating Factor (G-CSF)
  - 7.1.1.4. Interferons
  - 7.1.1.5. Recombinant Human Insulin
  - 7.1.1.6. Erythropoietin
  - 7.1.1.7. Vaccines
  - 7.1.1.8. Growth Hormones
  - 7.1.1.9. Purified Proteins
  - 7.1.1.10. Others
7.2. Latin America Biopharmaceutical Market Outlook, by Therapeutic Application, Value (US$ Bn), 2018 - 2031
- 7.2.1.1. Metabolic Disorders
- 7.2.1.2. Oncology
- 7.2.1.3. Neurological Disorders
- 7.2.1.4. Cardiovascular Diseases
- 7.2.1.5. Inflammatory and Infectious Diseases
- 7.2.1.6. Others
- 7.2.2. BPS Analysis/Market Attractiveness Analysis
7.3. Latin America Biopharmaceutical Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Brazil Biopharmaceutical Market by Type, Value (US$ Bn), 2018 - 2031
  - 7.3.1.2. Brazil Biopharmaceutical Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
  - 7.3.1.3. Mexico Biopharmaceutical Market by Type, Value (US$ Bn), 2018 - 2031
  - 7.3.1.4. Mexico Biopharmaceutical Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
  - 7.3.1.5. Argentina Biopharmaceutical Market by Type, Value (US$ Bn), 2018 - 2031
  - 7.3.1.6. Argentina Biopharmaceutical Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
  - 7.3.1.7. Rest of Latin America Biopharmaceutical Market by Type, Value (US$ Bn), 2018 - 2031
  - 7.3.1.8. Rest of Latin America Biopharmaceutical Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
- 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Biopharmaceutical Market Outlook, 2018 - 2031

8.1. Middle East & Africa Biopharmaceutical Market Outlook, by Type, Value (US$ Bn), 2018 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Monoclonal Antibodies
  - 8.1.1.2. Recombinant Proteins
  - 8.1.1.3. Granulocyte-Colony Stimulating Factor (G-CSF)
  - 8.1.1.4. Interferons
  - 8.1.1.5. Recombinant Human Insulin
  - 8.1.1.6. Erythropoietin
  - 8.1.1.7. Vaccines
  - 8.1.1.8. Growth Hormones
  - 8.1.1.9. Purified Proteins
  - 8.1.1.10. Others
8.2. Middle East & Africa Biopharmaceutical Market Outlook, by Therapeutic Application, Value (US$ Bn), 2018 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Metabolic Disorders
  - 8.2.1.2. Oncology
  - 8.2.1.3. Neurological Disorders
  - 8.2.1.4. Cardiovascular Diseases
  - 8.2.1.5. Inflammatory and Infectious Diseases
  - 8.2.1.6. Others
- 8.2.2. BPS Analysis/Market Attractiveness Analysis
8.3. Middle East & Africa Biopharmaceutical Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. GCC Biopharmaceutical Market by Type, Value (US$ Bn), 2018 - 2031
  - 8.3.1.2. GCC Biopharmaceutical Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
  - 8.3.1.3. South Africa Biopharmaceutical Market by Type, Value (US$ Bn), 2018 - 2031
  - 8.3.1.4. South Africa Biopharmaceutical Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
  - 8.3.1.5. Egypt Biopharmaceutical Market by Type, Value (US$ Bn), 2018 - 2031
  - 8.3.1.6. Egypt Biopharmaceutical Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
  - 8.3.1.7. Nigeria Biopharmaceutical Market by Type, Value (US$ Bn), 2018 - 2031
  - 8.3.1.8. Nigeria Biopharmaceutical Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
  - 8.3.1.9. Rest of Middle East & Africa Biopharmaceutical Market by Type, Value(US$Bn), 2018 - 2031
  - 8.3.1.10. Rest of Middle East & Africa Biopharmaceutical Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
- 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. Manufacturer vs by Therapeutic Application Heatmap
9.2. Company Market Share Analysis, 2023
9.3. Competitive Dashboard
9.4. Company Profiles
- 9.4.1. Abbott Laboratories
  - 9.4.1.1. Company Overview
  - 9.4.1.2. Product Portfolio
  - 9.4.1.3. Financial Overview
  - 9.4.1.4. Business Strategies and Development
- 9.4.2. Pfizer, Inc.
  - 9.4.2.1. Company Overview
  - 9.4.2.2. Product Portfolio
  - 9.4.2.3. Financial Overview
  - 9.4.2.4. Business Strategies and Development
- 9.4.3. Eli Lilly and Company
  - 9.4.3.1. Company Overview
  - 9.4.3.2. Product Portfolio
  - 9.4.3.3. Financial Overview
  - 9.4.3.4. Business Strategies and Development
- 9.4.4. Sanofi
  - 9.4.4.1. Company Overview
  - 9.4.4.2. Product Portfolio
  - 9.4.4.3. Financial Overview
  - 9.4.4.4. Business Strategies and Development
- 9.4.5. AbbVie Inc.
  - 9.4.5.1. Company Overview
  - 9.4.5.2. Product Portfolio
  - 9.4.5.3. Financial Overview
  - 9.4.5.4. Business Strategies and Development
- 9.4.6. Novartis AG
  - 9.4.6.1. Company Overview
  - 9.4.6.2. Product Portfolio
  - 9.4.6.3. Financial Overview
  - 9.4.6.4. Business Strategies and Development
- 9.4.7. AstraZeneca plc
  - 9.4.7.1. Company Overview
  - 9.4.7.2. Product Portfolio
  - 9.4.7.3. Financial Overview
  - 9.4.7.4. Business Strategies and Development
- 9.4.8. Amgen, Inc.
  - 9.4.8.1. Company Overview
  - 9.4.8.2. Product Portfolio
  - 9.4.8.3. Financial Overview
  - 9.4.8.4. Business Strategies and Development
- 9.4.9. Biogen Idec
  - 9.4.9.1. Company Overview
  - 9.4.9.2. Product Portfolio
  - 9.4.9.3. Financial Overview
  - 9.4.9.4. Business Strategies and Development
- 9.4.10. GlaxoSmithKline Plc
  - 9.4.10.1. Company Overview
  - 9.4.10.2. Product Portfolio
  - 9.4.10.3. Financial Overview
  - 9.4.10.4. Business Strategies and Development
- 9.4.11. Bristol-Myers Squibb Company
  - 9.4.11.1. Company Overview
  - 9.4.11.2. Product Portfolio
  - 9.4.11.3. Financial Overview
  - 9.4.11.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

List of Region/Countries

North America
- U.S.
- Canada

Europe
- Germany
- U.K.
- France
- Italy
- Turkey
- Russia
- Rest of Europe

Asia Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia Pacific

Latin America
- Brazil
- Mexico
- Rest of Latin America

Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa